Who
Anthony Welters
Director
Company insider
Files Form 4 as: Director, Gilead Sciences; Director, The Carlyle Group; Director, Loews; Director, Bard C R Inc /nj/; Director, West Pharmaceutical Services; EVP, UnitedHealth Group, UnitedHealth Group; Director, Qwest Communications International.
In numbers
- Trades disclosed
- 460
- Buys
- 2
- Sells
- 23
- Bought
- $559K
- Sold
- $26.6M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 30 Dec 2005
- Last trade
- 26 Aug 2026
- Last filed
- 27 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $468K7,718 at $60.67 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $462K3,118 at $148.31 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $685K4,600 at $148.82 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,718 at $0.00 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,282 at $0.00 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $631K10,282 at $61.35 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $504K3,402 at $148.24 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.0M6,880 at $148.82 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,718 at $0.00 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,282 at $0.00 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $468K7,718 at $60.67 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $462K3,118 at $148.31 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $685K4,600 at $148.82 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $631K10,282 at $61.35 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $504K3,402 at $148.24 | filing |
| 26 Aug 2026filed 27 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.0M6,880 at $148.82 | filing |
| 1 May 2026filed 1 May 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code A | —4,450 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code A | —4,450 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code A | —1,146 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,884 at $0.00 | filing |
News
7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A.GILD · dailypolitical.com · 24 Oct 2026Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Anthony Welters; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.